Actuate Therapeutics Inc (ACTU) Stock Analysis
Verdict: AVOID
FDA clearance for oral Elraglusib provides a clinical bridge, but a <9-month cash runway makes heavy dilution the primary risk factor.
Investment score: 38/100
Analysis as of
Is Actuate Therapeutics Inc stock worth reviewing? The TradeMates thesis
Clinical progress is overshadowed by an impending cash crunch and high valuation relative to biotech peers.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Actuate Therapeutics Inc opportunities and risks
What speaks for ACTU
- FDA IND Clearance for Oral Elraglusib
What speaks against ACTU
- Imminent Liquidity Crunch and Dilution
Peers and competitors
- FBIO
- KALA
- XGN
- OSTX
- ATRA
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ACTU | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.1% |
| FBIO | 9.3x | 1.2x | n/a | 66.9% | 10.8% | -90.4% |
| KALA | n/a | 0.0x | n/a | 0.0% | 0.0% | -38.0% |
| XGN | n/a | 1.4x | n/a | 58.3% | -29.5% | -15.1% |
| OSTX | n/a | 0.0x | 6.9x | 0.0% | 0.0% | -20.2% |
| ATRA | 3.4x | 0.6x | 3.2x | 82.4% | 27.1% | -68.0% |
| Peer median | n/a | 0.6x | n/a | 58.3% | 0.0% | -38.0% |
Frequently asked questions about Actuate Therapeutics Inc (ACTU)
Is ACTU stock a good investment?
The TradeMates model rates Actuate Therapeutics Inc as AVOID with an investment score of 38/100. Clinical progress is overshadowed by an impending cash crunch and high valuation relative to biotech peers. This is algorithmic model output, not personal investment advice.
Is ACTU stock a buy?
The TradeMates model verdict for ACTU is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.